1493EGP
- Active ingredient
- insulin degludec+liraglutide
- Strength
- 100 i.u + 3.6 mg/ml
- Form
- syringe
- Manufacturer
- novo nordisk
- Route
- injection
Uses
Used in adults with type 2 diabetes to improve glycemic control.
Do not use if
Hypersensitivity to components or personal/family history of medullary thyroid carcinoma.
Side effects
Hypoglycemia, nausea, diarrhea, and injection-site reactions may occur.
Warnings
Monitor for pancreatitis and hypoglycemia.
How it works
Combines basal insulin degludec with the GLP-1 receptor agonist liraglutide.
Storage
Store refrigerated before use.
